Sunday 18 October 2026
Export TNXP’s income statement to Excel — free account
Tonix Pharmaceuticals Holding Corp.
TNXP Healthcare Biotechnology
Tonix Pharmaceuticals Holding Corp.’s revenue for fiscal 2025 (year ended December 2025) was $13.1 million, up 29.8% from fiscal 2024. In the quarter to June 2026, revenue grew 577.9%, EPS grew 36.8% and free cash flow fell 178.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
6.04
0.38
−5.92%
Follow TNXP
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
— | — | — | — | — | — | — | — | — | 5 |
Altman Z-Score |
— | — | — | — | — | — | — | (7.57) | (7.62) | (2.42) |
P/S ratio |
— | — | — | — | — | — | — | 0.00 | 2.41 | 10.14 |
P/FCF ratio |
— | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | — | — | — | (14.34) | (9.93) | (0.37) |
Beneish M-Score |
— | — | — | — | — | — | — | — | — | (2.38) |
P/Operating CF |
— | — | — | — | — | — | — | (0.48) | (1.66) | (3.35) |
P/B ratio |
— | — | — | — | — | — | — | 0.10 | 0.17 | 0.54 |
Price to Tangible BV |
— | — | — | — | — | — | — | 0.11 | 0.17 | 0.54 |
EV/Sales |
— | — | — | — | — | — | — | 0.00 | (6.64) | (5.13) |
EV/EBITDA |
— | — | — | — | — | — | — | 0.05 | 0.51 | 0.54 |
EV/Operating CF |
— | — | — | — | — | — | — | 0.05 | 1.10 | 0.67 |
EV/FCF |
— | — | — | — | — | — | — | 0.05 | 1.10 | 0.65 |
Quick Ratio |
12.34 | 11.99 | 9.43 | 2.19 | 8.63 | 8.58 | 7.06 | 1.32 | 5.60 | 6.94 |
Current Ratio |
12.83 | 12.44 | 9.81 | 2.72 | 8.96 | 8.71 | 7.19 | 2.53 | 6.50 | 7.42 |
Net Debt/EBITDA |
0.67 | 1.20 | 0.95 | 0.38 | 1.50 | 1.93 | 1.08 | 0.14 | 0.69 | 1.68 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 2.46% | 1.34% | 0.40% | 0.34% | 5.77% | 4.60% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.04 | 0.02 | 0.00 | 0.00 | 0.08 | 0.05 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.06 | 0.06 |
Operating CF/Net income |
0.96 | 0.91 | 0.82 | 0.86 | 0.93 | 0.82 | 0.84 | 0.87 | 0.47 | 0.81 |
Capex/Depreciation |
(0.32) | (0.07) | (0.11) | (0.65) | (317.19) | (706.14) | (38.43) | (1.61) | (0.03) | (1.69) |
Interest Coverage |
306.84 | 126.73 | 112.97 | — | — | (3,692.48) | (59.85) | — | (110.78) | (1,412.39) |
| (118.38%) | (84.53%) | (121.60%) | (187.97%) | (107.50%) | (60.25%) | (54.88%) | (74.61%) | (106.12%) | (64.48%) | |
| (104.23%) | (77.85%) | (110.62%) | (152.12%) | (92.56%) | (54.43%) | (50.10%) | (61.38%) | (81.95%) | (56.37%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | (265.49%) | (140.67%) | (79.87%) | (82.68%) | (177.00%) | (209.43%) |
Return on Tangible Assets |
(154.29%) | (86.54%) | (125.21%) | (351.44%) | (60.15%) | (42.35%) | (56.62%) | (94.91%) | (90.97%) | (51.14%) |
Average Days of Receivables |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 133.18 | 174.63 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 1,115.54% | 396.00% | 339.41% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 447.37% | 397.28% | 668.99% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.07 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 119.40% | 47.34% | 45.91% |
Graham Net Nets |
— | — | — | — | — | — | — | (0.11) | 3.94 | 1.48 |
Graham Number |
— | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | — | — | — | — | — | — | (1,630.69%) | (7,684.39%) | (93.32%) |
Free Cash Flow Yield |
— | — | — | — | — | — | — | (1,025.65%) | (251.24%) | (77.63%) |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 983.29 | 13.71 | 1.54 |
Operating CF per Share |
(14.80) | (28.68) | (212.13) | (16.58) | (0.51) | (125,928.33) | (54,473.89) | (12,911.77) | (82.74) | (11.73) |
Capex per Share |
(0.03) | (0.01) | (0.05) | (0.01) | (0.09) | (58,845.00) | (26,748.33) | (872.91) | (0.16) | (0.40) |
Free Cash Flow per Share |
(14.83) | (28.69) | (212.19) | (16.59) | (0.60) | (184,773.33) | (81,222.22) | (13,784.68) | (82.91) | (12.13) |
Cash per Share |
10.36 | 38.22 | 221.54 | 6.99 | 0.81 | 297,766.67 | 66,793.89 | 3,157.97 | 134.15 | 24.40 |
Shareholders Equity per Share |
10.06 | 36.91 | 209.42 | 5.85 | 0.93 | 364,528.33 | 115,101.11 | 13,357.59 | 189.54 | 28.80 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
10.06 | 36.91 | 209.42 | 5.85 | 0.93 | 364,528.33 | 115,101.11 | 13,357.59 | 189.54 | 28.80 |
Free Cash Flow |
(37.38) | (19.13) | (23.98) | (26.70) | (57.13) | (110.86) | (146.20) | (108.90) | (61.04) | (103.21) |
Working Capital |
25.02 | 24.32 | 23.40 | 8.81 | 78.17 | 167.33 | 112.60 | 28.88 | 100.70 | 198.04 |
Capital Expenditures |
(0.07) | 0.00 | (0.01) | (0.02) | (8.56) | (35.31) | (48.15) | (6.90) | (0.12) | (3.37) |
Net Current Asset Value |
24.99 | 24.31 | 23.40 | 8.81 | 77.45 | 166.87 | 112.27 | (1.16) | 95.67 | 196.86 |
EV/EBIT |
— | — | — | — | — | — | — | 0.05 | 0.49 | 0.53 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.89 | 0.01 | 0.26 |
Price to Operating Income |
— | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
1.37 | 0.77 | 1.26 | 0.76 | 0.00 | 0.00 | 0.01 | 0.05 | 0.10 | 0.04 |
Cash ROIC |
(72.61%) | (38.18%) | (49.24%) | (127.00%) | (34.41%) | (27.83%) | (44.55%) | (78.13%) | (24.83%) | (22.80%) |
Accounts Receivable Turnover |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 1.72 | 2.63 |
Accounts Payable Turnover |
0.11 | 0.06 | 0.04 | 0.01 | 0.01 | 0.01 | 0.12 | 0.80 | 1.86 | 1.05 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.70 | 0.92 |
Average Days of Payables |
1,545.05 | 7,391.25 | 9,490.00 | 43,098.08 | 62,158.15 | 96,958.60 | 2,350.22 | 291.17 | 213.69 | 446.03 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1,050.04 | 395.22 | 330.53 |
Average Receivables |
— | — | — | — | 7.68 | 7.68 | 7.88 | — | 5.86 | 4.98 |
Average Payables |
1.96 | 1.08 | 1.35 | 2.24 | 3.83 | 8.94 | 10.68 | 5.93 | 4.16 | 6.33 |
Average Inventory |
— | — | — | — | — | — | — | — | 11.02 | 7.21 |
Average Assets |
37.26 | 27.13 | 26.54 | 20.44 | 56.37 | 169.54 | 233.30 | 190.07 | 158.67 | 220.03 |
Average Common Equity |
32.81 | 24.99 | 24.14 | 16.54 | 48.53 | 153.18 | 212.95 | 156.35 | 122.54 | 192.35 |
Columns are period end dates